ArticleBMJ public health2026
Seroprevalence of dengue virus infection and associated risk factors: a community-based cross-sectional survey in Burkina Faso.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Since 2017, dengue fever has been endemic in Burkina Faso. However, epidemiological data to guide effective dengue control policies remain limited in the country. To support decision-making with scientific evidence on the burden of dengue, this study aimed at estimating the seroprevalence of dengue infection in the population and to identify its potential risk factors. Methods: A nationwide, community-based cross-sectional survey including both urban and rural areas was conducted in May 2022 in Burkina Faso. A two-stage stratified cluster sampling design was used to select resident participants aged ≥5 years. Five millilitres of blood samples was obtained from each participant. Seroprevalence estimates were based on an IgG rapid test (sensitivity 95%, specificity 82%) and were not adjusted for misclassification. Data analysis accounted for the complex survey design including clustering, stratification and sampling weights. Multivariable logistic regression was used to identify factors associated with dengue seropositivity. Results: Overall seroprevalence was 39% (95% CI 37% to 41%) and was consistently higher in urban areas (50%) versus rural areas (24%). Seroprevalence varied significantly by geographic region, with the highest values observed in Centre, Centre-North and North. In multivariable analysis, urban residence was significantly associated with seropositivity (OR 2.35, 95% CI 1.81 to 3.05). Increasing age also showed a strong association, with the highest odds observed among participants aged ≥55 years (OR 10.32, 95% CI 7.42 to 14.35). Individuals with at least a primary education had higher odds of seropositivity (OR 1.25, 95% CI 1.01 to 1.55). In contrast, high socioeconomic status (SES) was associated with lower odds of seropositivity (OR 0.53, 95% CI 0.39 to 0.71). Conclusions: The observed seroprevalence suggests moderate transmission; however, interpretation for vaccination policy should be cautious given assay limitations and cross-sectional design. Findings indicate that urban residence, older age, lower SES and high education level are associated with higher dengue seroprevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.